Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report)‘s stock had its “outperform” rating restated by stock analysts at Wedbush in a note issued to investors on Tuesday,Benzinga reports. They currently have a $11.00 price target on the stock. Wedbush’s price target would suggest a potential upside of 192.94% from the company’s current price.
A number of other research firms also recently issued reports on CATX. UBS Group boosted their price objective on shares of Perspective Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, March 18th. B. Riley Financial boosted their price objective on shares of Perspective Therapeutics from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, March 18th. Truist Financial set a $12.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, March 17th. Piper Sandler started coverage on shares of Perspective Therapeutics in a report on Thursday, February 19th. They issued an “overweight” rating and a $16.00 price objective for the company. Finally, HC Wainwright upped their price target on shares of Perspective Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, March 23rd. One analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $12.63.
Check Out Our Latest Report on Perspective Therapeutics
Perspective Therapeutics Price Performance
Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last announced its quarterly earnings results on Monday, March 16th. The company reported ($0.51) EPS for the quarter. Perspective Therapeutics had a negative net margin of 11,665.27% and a negative return on equity of 41.79%. The company had revenue of $0.04 million during the quarter. On average, analysts forecast that Perspective Therapeutics will post -1.17 earnings per share for the current year.
Hedge Funds Weigh In On Perspective Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Patient Square Capital LP bought a new position in Perspective Therapeutics in the 3rd quarter valued at approximately $1,198,000. Siligmueller & Norvid Wealth Advisors LLC bought a new position in Perspective Therapeutics in the 3rd quarter valued at approximately $565,000. SG Americas Securities LLC bought a new position in Perspective Therapeutics in the 3rd quarter valued at approximately $46,000. Abel Hall LLC bought a new position in Perspective Therapeutics in the 1st quarter valued at approximately $49,000. Finally, Wealth Effects LLC lifted its stake in Perspective Therapeutics by 32.0% in the 1st quarter. Wealth Effects LLC now owns 33,000 shares of the company’s stock valued at $138,000 after purchasing an additional 8,000 shares during the last quarter. Institutional investors own 54.66% of the company’s stock.
Perspective Therapeutics Company Profile
Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Featured Stories
Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
